Executive search firm Toft Group has placed Mr. Scott Generes as Director of Business Development at Retrophin, Inc., in San Diego, CA. Mr. Generes is a senior executive offering 15 years of finance, strategic planning and business development experience within the biotechnology arena. He most recently served with Gradalis, Inc., as their Senior Director, Finance and Strategic Planning. He earned an MBA from UCLA.
About Retrophin, Inc.
Retrophin, Inc. (NASDAQ:RTRX) is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company is focused on advancing the development of its lead pipeline assets: sparsentan for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease; and RE-024 for pantothenate kinase associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood.